Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) has been given a $17.00 price target by equities research analysts at HC Wainwright in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock.
The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating but are lowering our price target to $17 from $19.50. The factors impacting our valuation include: (1) change to base year; (2) adjustment to fully diluted share count of of October 2018 equity raise; and (3) increasing our chance of success for RX-3117 in first-line pancreatic cancer from 20% to 25%. Our target is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, RX-3117, and RX-5902 (Supinoxin).””
Several other equities analysts also recently commented on the company. Ifs Securities upgraded Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, October 4th. B. Riley set a $8.00 target price on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Friday, August 10th. Finally, Brookline Cap M restated a “buy” rating on shares of Rexahn Pharmaceuticals in a research report on Tuesday, November 27th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Rexahn Pharmaceuticals has a consensus rating of “Buy” and an average price target of $8.75.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its earnings results on Monday, November 5th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17).
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Further Reading: What is the LIBOR?
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.